ASSERTIO HOLDINGS INC (ASRT) Stock Price, Forecast & Analysis
NASDAQ:ASRT • US04546C3043
ASRT Key Statistics, Chart & Performance
The current stock price of ASRT is 11.95 USD. In the past month the price increased by 15.63%. In the past year, price decreased by -5.34%.
ASRT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ASRT. When comparing the yearly performance of all stocks, ASRT is a bad performer in the overall market: 70.4% of all stocks are doing better.
ASRT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ASRT. ASRT may be in some trouble as it scores bad on both profitability and health.
ASRT Financial Highlights
Over the last trailing twelve months ASRT reported a non-GAAP Earnings per Share(EPS) of -3. The EPS increased by 72.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.9% | ||
| ROE | -26.89% | ||
| Debt/Equity | 0.37 |
ASRT Forecast & Estimates
10 analysts have analysed ASRT and the average price target is 38.19 USD. This implies a price increase of 219.55% is expected in the next year compared to the current price of 11.95.
For the next year, analysts expect an EPS growth of -90.1% and a revenue growth -9.11% for ASRT
ASRT Ownership
ASRT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.25 | 959.759B | ||
| JNJ | JOHNSON & JOHNSON | 20.67 | 580.304B | ||
| MRK | MERCK & CO. INC. | 22.05 | 296.13B | ||
| PFE | PFIZER INC | 9.23 | 157.665B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.85 | 122.002B | ||
| ZTS | ZOETIS INC | 18.74 | 56.704B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.53 | 25.543B | ||
| VTRS | VIATRIS INC | 6.38 | 18.578B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.59 | 12.774B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.37 | 9.387B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ASRT
Company Profile
Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 58 full-time employees. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Company Info
ASSERTIO HOLDINGS INC
100 S. Saunders Road, Suite 300
Lake Forest ILLINOIS 60045 US
CEO: Daniel A. Peisert
Employees: 58
Phone: 12244197106
ASSERTIO HOLDINGS INC / ASRT FAQ
Can you describe the business of ASSERTIO HOLDINGS INC?
Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 58 full-time employees. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
What is the stock price of ASSERTIO HOLDINGS INC today?
The current stock price of ASRT is 11.95 USD. The price increased by 2.31% in the last trading session.
Does ASRT stock pay dividends?
ASRT does not pay a dividend.
What is the ChartMill rating of ASSERTIO HOLDINGS INC stock?
ASRT has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for ASSERTIO HOLDINGS INC?
ASSERTIO HOLDINGS INC (ASRT) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for ASRT stock?
ASSERTIO HOLDINGS INC (ASRT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3).
What is ASSERTIO HOLDINGS INC worth?
ASSERTIO HOLDINGS INC (ASRT) has a market capitalization of 1.15B USD. This makes ASRT a Small Cap stock.